Halozyme Therapeutics (NASDAQ:HALO) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $50.00 price target on the biopharmaceutical company’s stock.

HALO has been the subject of a number of other reports. TD Cowen began coverage on Halozyme Therapeutics in a research report on Thursday, February 29th. They set an outperform rating and a $54.00 price target for the company. StockNews.com raised Halozyme Therapeutics from a hold rating to a buy rating in a research report on Friday, February 23rd. Benchmark reaffirmed a buy rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday. JMP Securities reaffirmed a market outperform rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. Finally, Morgan Stanley decreased their price target on Halozyme Therapeutics from $61.00 to $59.00 and set an overweight rating for the company in a research report on Tuesday, December 26th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $53.29.

Halozyme Therapeutics Stock Down 0.9 %

HALO stock opened at $38.02 on Wednesday. Halozyme Therapeutics has a twelve month low of $29.85 and a twelve month high of $45.00. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. The stock’s 50 day moving average is $39.44 and its 200-day moving average is $37.76. The firm has a market capitalization of $4.83 billion, a PE ratio of 18.02, a P/E/G ratio of 0.46 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The company had revenue of $230.04 million during the quarter, compared to the consensus estimate of $235.25 million. Sell-side analysts expect that Halozyme Therapeutics will post 3.33 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $39.55, for a total value of $395,500.00. Following the sale, the senior vice president now directly owns 156,558 shares in the company, valued at $6,191,868.90. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 30,000 shares of company stock worth $1,196,800 over the last ninety days. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in HALO. TD Asset Management Inc raised its stake in shares of Halozyme Therapeutics by 517.0% during the 4th quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock valued at $73,326,000 after purchasing an additional 1,662,390 shares during the period. Norges Bank bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at $44,935,000. Epoch Investment Partners Inc. raised its stake in shares of Halozyme Therapeutics by 250.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock valued at $42,986,000 after purchasing an additional 831,199 shares during the period. Macquarie Group Ltd. raised its stake in shares of Halozyme Therapeutics by 22.8% during the 1st quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock valued at $122,226,000 after purchasing an additional 595,220 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Halozyme Therapeutics by 174.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock valued at $33,894,000 after purchasing an additional 563,989 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.